These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21180532)

  • 1. Current status of therapy in nonalcoholic Fatty liver disease.
    McNear S; Harrison SA
    Therap Adv Gastroenterol; 2009 Jan; 2(1):29-43. PubMed ID: 21180532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Wong T; Wong RJ; Gish RG
    Gastroenterol Hepatol (N Y); 2019 Feb; 15(2):83-89. PubMed ID: 31011302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR; Torres DM; Harrison SA
    Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the understanding and treatment of nonalcoholic fatty liver disease.
    Harrison SA; Di Bisceglie AM
    Drugs; 2003; 63(22):2379-94. PubMed ID: 14609346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease in South Asia.
    Pati GK; Singh SP
    Euroasian J Hepatogastroenterol; 2016; 6(2):154-162. PubMed ID: 29201749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
    Chen Y; Wang W; Morgan MP; Robson T; Annett S
    Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
    Kluwe J; Lohse AW
    Internist (Berl); 2005 Dec; 46(12):1324-30. PubMed ID: 16247633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
    Long MT; Noureddin M; Lim JK
    Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.
    Ching-Yeung Yu B; Kwok D; Wong VW
    J Clin Exp Hepatol; 2019; 9(4):491-496. PubMed ID: 31516265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
    Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
    Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
    Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
    Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of nonalcoholic fatty liver disease.
    Mehta SR
    Ther Adv Endocrinol Metab; 2010 Jun; 1(3):101-15. PubMed ID: 23148155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions.
    Campbell P; Symonds A; Barritt AS
    Clin Ther; 2021 Mar; 43(3):500-517. PubMed ID: 33583577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD).
    Mishra P; Younossi ZM
    Curr Drug Discov Technol; 2007 Aug; 4(2):133-40. PubMed ID: 17691915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.